Benjamin Hohl Sells 991 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 991 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $27.53, for a total transaction of $27,282.23. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, July 29th, Benjamin Hohl sold 5,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $26.68, for a total transaction of $140,070.00.
• On Friday, July 12th, Benjamin Hohl sold 3,000 shares of Enliven Therapeutics stock. The stock was sold at an average price of $25.07, for a total transaction of $75,210.00.
• On Thursday, June 27th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $22.57, for a total transaction of $95,922.50.
• On Tuesday, May 28th, Benjamin Hohl sold 4,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $23.18, for a total transaction of $98,515.00.

Enliven Therapeutics Trading Down 6.0 %

Shares of NASDAQ ELVN traded down $1.48 during midday trading on Friday, reaching $23.22. The company’s stock had a trading volume of 261,164 shares, compared to its average volume of 273,318. The company has a 50 day moving average price of $22.84 and a 200 day moving average price of $19.49. Enliven Therapeutics, Inc. has a one year low of $9.80 and a one year high of $27.67. The company has a market cap of $1.09 billion, a price-to-earnings ratio of -11.66 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Tuesday, May 14th. The company reported ($0.54) EPS for the quarter, topping analysts’ consensus estimates of ($0.58) by $0.04. Research analysts anticipate that Enliven Therapeutics, Inc. will post -2.26 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ELVN has been the subject of a number of research analyst reports. Robert W. Baird initiated coverage on shares of Enliven Therapeutics in a research note on Tuesday, June 11th. They issued an “outperform” rating and a $32.00 price target for the company. Baird R W raised shares of Enliven Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Mizuho initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price on the stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of large investors have recently made changes to their positions in the company. Rhumbline Advisers raised its holdings in shares of Enliven Therapeutics by 29.9% during the second quarter. Rhumbline Advisers now owns 49,627 shares of the company’s stock valued at $1,160,000 after acquiring an additional 11,420 shares during the period. Bank of New York Mellon Corp raised its holdings in shares of Enliven Therapeutics by 49.2% during the second quarter. Bank of New York Mellon Corp now owns 114,109 shares of the company’s stock valued at $2,667,000 after acquiring an additional 37,632 shares during the period. Janus Henderson Group PLC increased its stake in Enliven Therapeutics by 74.8% in the 1st quarter. Janus Henderson Group PLC now owns 713,911 shares of the company’s stock valued at $12,604,000 after buying an additional 305,397 shares during the period. Blackstone Inc. acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $443,000. Finally, Baker BROS. Advisors LP acquired a new position in Enliven Therapeutics in the 1st quarter valued at approximately $2,020,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.